172 related articles for article (PubMed ID: 34113545)
1. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.
Solano VM; Mandujano CYC; Avila-Rejon CA; Espin VH; Montaño HPQ
Mol Genet Metab Rep; 2021 Sep; 28():100769. PubMed ID: 34113545
[TBL] [Abstract][Full Text] [Related]
2. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
[TBL] [Abstract][Full Text] [Related]
3. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.
Lee SH; Kim HY; Cho TJ; Kim H; Ko JM
Mol Genet Metab Rep; 2022 Jun; 31():100869. PubMed ID: 35782601
[TBL] [Abstract][Full Text] [Related]
6. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose.
Lachman RS; Burton BK; Clarke LA; Hoffinger S; Ikegawa S; Jin DK; Kano H; Kim OH; Lampe C; Mendelsohn NJ; Shediac R; Tanpaiboon P; White KK
Skeletal Radiol; 2014 Mar; 43(3):359-69. PubMed ID: 24389823
[TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt.
Fateen E; Abdallah ZY; Nazim WS; Ibrahim M; Radwan A
Heliyon; 2021 Aug; 7(8):e07830. PubMed ID: 34471711
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes.
Politei J; Porras-Hurtado GL; Guelbert N; Fainboim A; Horovitz DDG; Satizábal JM
JIMD Rep; 2021 Mar; 58(1):104-113. PubMed ID: 33728253
[TBL] [Abstract][Full Text] [Related]
10. Spondyloepiphyseal dysplasias and bilateral legg-calvé-perthes disease: diagnostic considerations for mucopolysaccharidoses.
Mendelsohn NJ; Wood T; Olson RA; Temme R; Hale S; Zhang H; Read L; White KK
JIMD Rep; 2013; 11():125-32. PubMed ID: 23657977
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
[TBL] [Abstract][Full Text] [Related]
12. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
13. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
[TBL] [Abstract][Full Text] [Related]
14. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa.
Mitchell JJ; Burton BK; Bober MB; Campeau PM; Cohen S; Dosenovic S; Ellaway C; Bhattacharya K; Guffon N; Hinds D; Lail A; Lin SP; Magner M; Raiman J; Schwartz-Sagi L; Stepien KM
Mol Genet Metab; 2022; 137(1-2):164-172. PubMed ID: 36087504
[TBL] [Abstract][Full Text] [Related]
15. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment.
Tomatsu S; Montaño AM; Oikawa H; Smith M; Barrera L; Chinen Y; Thacker MM; Mackenzie WG; Suzuki Y; Orii T
Curr Pharm Biotechnol; 2011 Jun; 12(6):931-45. PubMed ID: 21506915
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study.
de Almeida-Barros RQ; de Medeiros PFV; de Almeida Azevedo MQ; de Oliveira Lira Ortega A; Yamamoto ATA; Dornelas SKL; Bento PM
Clin Oral Investig; 2018 Jan; 22(1):201-208. PubMed ID: 28315965
[TBL] [Abstract][Full Text] [Related]
18. Cervical cord compression in mucopolysaccharidosis VI (MPS VI): Findings from the MPS VI Clinical Surveillance Program (CSP).
Solanki GA; Sun PP; Martin KW; Hendriksz CJ; Lampe C; Guffon N; Hung A; Sisic Z; Shediac R; Harmatz PR;
Mol Genet Metab; 2016 Aug; 118(4):310-8. PubMed ID: 27339555
[TBL] [Abstract][Full Text] [Related]
19. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
20. Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series.
İnci A; Okur İ; Tümer L; Biberoğlu G; Öktem M; Ezgü F
Orphanet J Rare Dis; 2021 Oct; 16(1):438. PubMed ID: 34666789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
